Bone biopsy protocol for advanced prostate cancer in the era of precision medicine.

Sailer, Verena; Schiffman, Marc H; Kossai, Myriam; Cyrta, Joanna; Beg, Shaham; Sullivan, Brian; Pua, Bradley B; Lee, Kyungmouk Steve; Talenfeld, Adam D; Nanus, David M; Tagawa, Scott T; Robinson, Brian D; Rao, Rema A; Pauli, Chantal; Bareja, Rohan; Beltran, Luis S; Sigaras, Alexandros; Eng, Kenneth Wa; Elemento, Olivier; Sboner, Andrea; ... (2018). Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer, 124(5), pp. 1008-1015. John Wiley & Sons 10.1002/cncr.31173

[img] Text
Sailer_et_al-2017-Cancer.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (494kB) | Request a copy

BACKGROUND Metastatic biopsies are increasingly being performed in patients with advanced prostate cancer to search for actionable targets and/or to identify emerging resistance mechanisms. Due to a predominance of bone metastases and their sclerotic nature, obtaining sufficient tissue for clinical and genomic studies is challenging. METHODS Patients with prostate cancer bone metastases were enrolled between February 2013 and March 2017 on an institutional review board-approved protocol for prospective image-guided bone biopsy. Bone biopsies and blood clots were collected fresh. Compact bone was subjected to formalin with a decalcifying agent for diagnosis; bone marrow and blood clots were frozen in optimum cutting temperature formulation for next-generation sequencing. Frozen slides were cut from optimum cutting temperature cryomolds and evaluated for tumor histology and purity. Tissue was macrodissected for DNA and RNA extraction, and whole-exome sequencing and RNA sequencing were performed. RESULTS Seventy bone biopsies from 64 patients were performed. Diagnostic material confirming prostate cancer was successful in 60 of 70 cases (85.7%). The median DNA/RNA yield was 25.5 ng/μL and 16.2 ng/μL, respectively. Whole-exome sequencing was performed successfully in 49 of 60 cases (81.7%), with additional RNA sequencing performed in 20 of 60 cases (33.3%). Recurrent alterations were as expected, including those involving the AR, PTEN, TP53, BRCA2, and SPOP genes. CONCLUSIONS This prostate cancer bone biopsy protocol ensures a valuable source for high-quality DNA and RNA for tumor sequencing and may be used to detect actionable alterations and resistance mechanisms in patients with bone metastases. Cancer 2017. © 2017 American Cancer Society.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie
04 Faculty of Medicine > Pre-clinic Human Medicine > BioMedical Research (DBMR) > DBMR Forschung Mu35 > Forschungsgruppe Präzisionsonkologie

UniBE Contributor:

Rubin, Mark Andrew

Subjects:

500 Science
500 Science > 570 Life sciences; biology

ISSN:

0008-543X

Publisher:

John Wiley & Sons

Language:

English

Submitter:

Marla Rittiner

Date Deposited:

12 Feb 2018 09:12

Last Modified:

23 Oct 2019 13:30

Publisher DOI:

10.1002/cncr.31173

PubMed ID:

29266381

Uncontrolled Keywords:

DNA RNA biopsy bone metastases next-generation sequencing (NGS) precision medicine prostate cancer

BORIS DOI:

10.7892/boris.110727

URI:

https://boris.unibe.ch/id/eprint/110727

Actions (login required)

Edit item Edit item
Provide Feedback